Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 6/20 | 0.49 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.44 |
| ▸ | CTSG | P08311 | 3/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | LDLR | P01130 | 5/20 | 0.41 |
| ▸ | PCSK9 | Q8NBP7 | 5/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | GRB7 | Q14451 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23104927 | 0.91 | CTSG (0.50) | OPRK1EPHA2CTSGPLAULDLR | |
| SCHEMBL23104900 | 0.89 | CTSG (0.51) | OPRK1EPHA2CTSGPLAULDLR | |
| SCHEMBL20385922 | 0.88 | CTSG (0.45) | OPRK1EPHA2CTSGPLAULDLR | |
| SCHEMBL20385895 | 0.87 | GRB7 (0.49) | OPRK1EPHA2CTSGPLAULDLR | |
| SCHEMBL20385944 | 0.87 | GRB7 (0.49) | OPRK1EPHA2CTSGPLAULDLR | |
| SCHEMBL20382863 | 0.86 | CTSG (0.51) | OPRK1EPHA2CTSGPLAULDLR | |
| SCHEMBL20382865 | 0.86 | CTSG (0.51) | OPRK1EPHA2CTSGPLAULDLR | |
| SCHEMBL23105035 | 0.85 | CTSG (0.48) | OPRK1EPHA2CTSGPLAULDLR | |
| SCHEMBL22198564 | 0.84 | CTSG (0.59) | OPRK1EPHA2CTSGPLAULDLR | |
| SCHEMBL20756513 | 0.84 | CTSG (0.59) | OPRK1EPHA2CTSGPLAULDLR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10624968-B2 | Compounds for treating cancer | Bicyclerd Limited (GB) | 2020-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10624968-B2 | Compounds for treating cancer | TP53, VHL, MYC | OPRK1 3279/4885EPHA2 1788/4885CTSG 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.